Intestinal complications in patients with Crohn’s disease in the Brazilian public healthcare system between 2011 and 2020

Table 1 Demographic characteristics and follow-up of patients with Crohn’s disease at Sistema Único de Saúde: General, conventional therapy-only, and anti-tumor necrosis factor therapy population, n (%)

	General patients with CD	CVT-only	Anti-TNF therapy
Patients	16809 (100)	12163 (72)	4646 (28)
Age, yr
Mean (SD)	44.09 (15.38)4	46.37 (15.42)	39.98 (13.72)5
Median (IQR)	43.27 (31.31–55.33)4	46.06 (34.10-57.62)	37.53 (28.59-50.47)5
Gender
Male	6804 (40)	4686 (39)	2118 (46)
Female	10005 (60)	7477 (61)	2528 (54)
Ethnicity, n (%)
Caucasian	8877 (53)	6214 (51)	2663 (57)
Mixed	5002 (29)	3108 (26)	1330 (29)
Black	622 (4)	451 (4)	171 (4)
Missing/others	2308 (14)	2390 (19)	482 (10)
Region of residence
Southeast	10241 (61)	7085 (58)	3156 (68)
South	2369 (14)	1765 (15)	604 (13)
Midwest	756 (4)	491 (4)	265 (6)
Northeast	3188 (19)	2668 (22)	520 (11)
North	254 (2)	153 (1.3)	101 (2)
Missing	1 (0)	1 (0.01)	0 (0)
Follow-up time1, yr
Mean (SD)	4.44 (2.37)	4.3 (2.36)	4.86 (2.35)
Median (IQR)	4.34 (2.42–6.34)	4.17 (2.25–6.17)	4.84 (2.92–6.84)
CVT
Mesalazine	12423 (74)	9376 (77)	3145 (68)
Sulfasalazine	2458 (15)	1864 (15)	619 (13)
Azathioprine	7078 (42)	4012 (33)	3126 (67)
Methotrexate	318 (2)	180 (1.5)	140 (3)
Anti-TNF therapy
Infliximab	2737 (16)	-	2737 (59)
Adalimumab	2378 (14)	-	2378 (51)
Certolizumab	145 (0.8)	-	145 (3)
Time using CVT2, years
Mean (SD)	3.22 (2.46)	3.16 (2.46)	1.84 (1.75)
Median (IQR)	2.67 (1.08–5.00)	2.59 (1.00–4.92)	1.25 (0.50–2.61)
Time using anti-TNF therapy3, yr
Mean (SD)	-	-	2.39 (2.06)
Median (IQR)	-	-	1.76 (0.67–3.67)
Time using CVT therapy prior to anti-TNF therapy
Mean (SD)	-	1.84 (1.75)	-
Median (IQR)	-	1.25 (0.50–2.61)	-
Immunosuppressant therapy prior to anti-TNF therapy, n (%)	-	-	2603 (56)

¹Time since index date conventional therapy up to the last date of patient information available in the database.

²Calculated based on the index date and the last claim of conventional therapy.

³Calculated based on the anti-tumor necrosis factor drug initiation date and the last date of patient information available in the database.

⁴Age at the index date (conventional therapy initiation).

⁵Age at the initiation of anti-tumor necrosis factor therapy.

Conventional therapy and/or anti-tumor necrosis factor therapy describes the proportion of patients who have used each drug. Patients could use one or more drugs, alone or in combination. Immunosuppressant therapy: Azathioprine and/or methotrexate. CD: Crohn’s disease; CVT: Conventional therapy; SUS: Sistema Único de Saúde; TNF: Tumor necrosis factor; IQR: Interquartile range.